Rentschler Biopharma SE, a global biopharmaceuticals CDMO, including advanced therapy medicinal products (ATMPs), and Ikarovec, which is developing novel multicistronic gene therapies to treat major ophthalmic indications, have entered into a collaboration. Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy. This condition is an adva...